Jan 8 (Reuters) - Cellectar Biosciences said on Monday its therapy iopofosine for Waldenstrom's macroglobulinemia, a type of blood cancer, met the main goal when tested in patients who received at least two prior lines of therapy. (Reporting by Christy Santhosh; Editing by Shounak Dasgupta)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.505 USD | -13.32% | -9.64% | -8.66% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.66% | 104M | |
+54.52% | 811B | |
+43.62% | 640B | |
-6.72% | 353B | |
+18.05% | 333B | |
+8.69% | 302B | |
+16.30% | 246B | |
+2.41% | 225B | |
+12.47% | 218B | |
+9.23% | 168B |
- Stock Market
- Equities
- CLRB Stock
- News Cellectar Biosciences, Inc.
- Cellectar's blood cancer therapy succeeds in trial